SGMT
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.00M | 0 | 0 | 0 | 0 |
| Net Income | (51.04M) | (45.57M) | (27.88M) | (30.50M) | (24.44M) | (11.37M) | (14.26M) |
| EPS | -1.58 | -1.45 | -1.53 | -1.38 | -1.10 | -0.51 | -0.64 |
| Free Cash Flow | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| FCF / Share | -1.41 | -1.35 | -1.31 | -1.10 | -0.98 | -0.47 | -0.48 |
| Operating CF | (45.65M) | (42.44M) | (23.77M) | (24.49M) | (21.71M) | (10.42M) | (10.55M) |
| Total Assets | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M | 68.96M | 11.16M |
| Total Debt | 78,000 | 78,000 | 65,000 | 211,000 | 348,000 | 210,000 | 341,000 |
| Cash & Equiv | 35.02M | 75.84M | 75.14M | 158,000 | 56.73M | 68.70M | 10.21M |
| Book Value | 111.38M | 155.81M | 91.06M | (186.95M) | (158.26M) | (135.91M) | (125.31M) |
| Return on Equity | -0.46 | -0.29 | -0.31 | N/A | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.00M |
| Net Income | (13.95M) | (10.65M) | (9.57M) | (12.91M) | (10.39M) | (18.18M) | (16.20M) | (14.62M) | (8.12M) | (6.63M) | (8.15M) | (6.35M) |
| EPS | -0.26 | -0.33 | -0.29 | -0.40 | -0.32 | -0.56 | -0.50 | -0.45 | -0.25 | -0.23 | -0.45 | -0.35 |
| Free Cash Flow | (10.70M) | (8.61M) | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) |
| FCF / Share | -0.20 | -0.26 | -0.36 | -0.31 | -0.28 | -0.45 | -0.34 | -0.61 | -0.18 | -0.21 | -0.39 | -0.21 |
| Operating CF | (10.70M) | (8.61M) | (11.83M) | (10.18M) | (9.10M) | (14.54M) | (11.02M) | (19.57M) | (5.63M) | (6.21M) | (7.08M) | (3.88M) |
| Total Assets | 263.43M | 107.75M | 116.48M | 128.40M | 137.41M | 146.17M | 160.26M | 174.78M | 189.02M | 194.53M | 96.72M | 102.92M |
| Total Debt | 1.94M | 39,000 | 78,000 | 115,000 | 152,000 | 39,000 | 78,000 | 116,000 | 153,000 | 26,000 | 65,000 | 103,000 |
| Cash & Equiv | 165.90M | 36.63M | 35.02M | 32.50M | 42.33M | 64.72M | 75.84M | 77.01M | 95.96M | 176.78M | 75.14M | 101.84M |
| Book Value | 256.15M | 102.46M | 111.38M | 119.25M | 130.16M | 138.99M | 155.81M | 170.68M | 183.29M | 190.02M | 91.06M | 97.88M |
| Return on Equity | -0.05 | -0.10 | -0.09 | -0.11 | -0.08 | -0.13 | -0.10 | -0.09 | -0.04 | -0.03 | -0.09 | -0.06 |
